Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dotamtate Pb-212
- Development stage
- Phase 2
- Lead developer
- Radiomedix
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Dotamtate Pb-212 (also known as 212Pb-DOTAMTATE or AlphaMedix) is a targeted radiopharmaceutical therapy designed for the treatment of somatostatin receptor-positive neuroendocrine tumors (NETs). It consists of three main components: the radioisotope Lead-212 (an in vivo generator of alpha-emitting particles), the chelator DOTAM (which stably binds Lead-212), and the somatostatin analogue Dotamtate that targets somatostatin receptors—particularly SSTR2—on tumor cells. Upon intravenous administration, Dotamtate Pb-212 selectively binds to SSTR-expressing tumor cells and delivers potent alpha radiation directly to these malignant cells. The short-range but high-energy alpha emissions induce complex DNA damage in target cells, leading to cell death while minimizing harm to surrounding healthy tissue. This mechanism offers an advantage over beta-emitting therapies by providing more effective cytotoxicity for resistant or advanced NETs. Clinical development has included Phase I and II trials for NETs[1][4][5][6].
- Brand names
- alphamedix
- Other names
- lead-212 dotamtatelead212 dotamtatelead 212 dotamtatepb-212-dotamtatepb212-dotamtatepb 212-dotamtate
02
Targets
SSTR (Somatostatin receptors)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on Dotamtate Pb-212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dotamtate Pb-212.